Users discuss finding reliable sources for RU58841, focusing on lab tests, batch consistency, and community reputation. Some mention using alternatives like pyrilutamide.
The conversation discusses various hair loss treatments, with a focus on pyrilutamide, minoxidil, and alternatives to finasteride due to intolerance. Users suggest adding a DHT blocker like finasteride or dutasteride, and some recommend trying topical versions to reduce side effects.
Low-level laser therapy hats for hair loss, with skepticism about their effectiveness and cost. Users suggest trying affordable alternatives instead of expensive options.
The conversation is about creating a natural hair loss topical using ingredients like cetirizine, Zinc Sulphate Heptahydrate, Safflower Extract, Ricinoleic Acid, and others. The user is seeking input and collaboration on this topical formula.
Creatine may increase DHT levels, potentially affecting hair loss, but evidence is mostly anecdotal. A study to explore this was withdrawn due to funding issues.
A user shared their positive experience with Roots by GA, a company that creates personalized hair loss treatments based on DNA analysis, which confirmed their inability to tolerate finasteride. The user is satisfied with their progress 30 days after a hair transplant and the customized formula they received.
A 33-year-old man experienced diffuse thinning and hair shedding due to sleep deprivation and low testosterone. After starting hCG treatment, he noticed hair regrowth on his temples.
Hair regrowth and gender transition using finasteride, estrogen, and spironolactone. Significant hair regrowth and personal transformation were achieved through hormone replacement therapy.
PP405 is a promising new treatment for hair loss that activates dormant stem cells in hair follicles, potentially bypassing the effects of DHT. It is currently in phase 2 trials and could be available between 2027 and 2030, but it is not considered a definitive cure.
The conversation is about someone experiencing continued hair loss despite using Pyrilutamide and considering the need for more time or better quality control for the treatment. Another person suggests waiting for the drug to be officially approved due to potential quality issues with current products.
A user wants to try melatonin for hair loss by mixing melatonin powder with a topical oil serum. They are asking if this mixture is possible and effective.
The user is using multiple topical treatments including Minoxidil, RU58841, and Spironolactone, along with supplements, to address hair loss and is considering starting oral Minoxidil. They plan to begin oral finasteride soon after experiencing side effects from topical dutasteride.
The conversation is about identifying ingredients in a scalp serum and their effects on DHT levels. The serum contains various ingredients like Aqua, Biotin, and Oleanolic Acid.
User discusses using C60 serum with microneedling at 1.75mm and asks if it's safe. Current routine includes daily Pyril on temples, weekly microneedling, and C60 serum on non-Pyril days.
Pelage executives' hairlines were discussed, with speculation about them using PP405 for hair regrowth. Concerns were raised about using untested drugs, with some suggesting executives might not risk using them without safety data.
P5P supplementation helped reverse finasteride side effects, particularly by lowering prolactin levels and restoring sensitivity. The user experienced significant improvement within a day and full recovery in a few days.
A user diluted a Hims spray with Kirkland's minoxidil to lower finasteride concentration and has been applying it for nearly 3 months, noticing baby hairs at the temples. They also use a dermastamp, saw palmetto, and biotin supplements, and are seeking advice on their hair loss stage.
The potential stability of pyrilutamide in a mixture with water, and how it could be used in combination with Minoxidil and Finasteride to treat hair loss.
Visible hair improvement after 10 weeks using minoxidil, estradiol enanthate, acetophenide algestone, and bicalutamide. The user is a 25-year-old male with reduced testosterone levels, expressing a preference for less masculinity.
HMI-115, a potential treatment for hair loss that can reverse miniaturization and make individual hairs thicker, as evidenced by data from macaques given the treatment and one subject in the phase I trial.
The discussion is about a hair loss drug called pyrilutamide. Users discuss its efficacy, safety, and expected market release around 2025-2026, with some expressing concerns about the authenticity of current market offerings.
Topical finasteride is currently more effective than pyrilutamide for hair loss. Combining treatments like topical finasteride and pyrilutamide may enhance results due to different mechanisms.
The conversation discusses the molecular structures of compounds that reduce DHT levels, including finasteride and Ashwagandha. It explores the potential of using Ashwagandha topically as a 5a reductase inhibitor.
GHK-Cu and Acetyl Tetrapeptide-3 are ineffective for hair regrowth according to user experiences. Effective treatments mentioned are finasteride, dutasteride, and minoxidil.
Despite using 5% minoxidil, 0.1% finasteride, and other treatments like microneedling, MK-677, and Cialis, hair loss continues with high testosterone and DHT levels. Considering oral dutasteride but concerned about further increasing testosterone levels.
A user is seeking a pharmacy to compound a topical solution containing Minoxidil, Finasteride, Alfatradiol, Melatonin, Latanoprost, and either RU58841 or Pyrilutamide. They prefer a professional compounding lab over DIY methods.
The user underwent a second hair transplant for the crown and mid-scalp, achieving good density. They are using minoxidil, finasteride, and biotin, and considering PRP treatments to enhance growth.
The conversation is about the difficulty of applying both pyril and min/fin to treat hair loss twice daily and whether combining them yields positive results.
There is no new information on pp405, with data collection expected to finish by the end of 2025. Users are discussing the timeline for data analysis and completion of Pelage Pharmaceuticals' phase 2 study.